← Eichor
Condition: Refractory Metastatic Colorectal Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Refractory Metastatic Colorectal Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06530303Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Phase 1/Phase 2 · 1 location(s) · Dan Feng · NCT07281716Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem
Phase 1/Phase 2 · 6 location(s) · National Cancer Institute (NCI) · NCT07147231Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treat
Phase 2 · 14 location(s) · Delcath Systems Inc. · NCT06607458Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases
Phase N/A · 1 location(s) · Aarhus University Hospital · NCT04491929CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Phase 3 · 6 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT07361003Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Met
Phase 2 · 9 location(s) · Barbara Ann Karmanos Cancer Institute · NCT07130903Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Re
NA · 1 location(s) · Charite University, Berlin, Germany · NCT05991102Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tip
Phase 2 · 2 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT06522919Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Phase 2 · 2 location(s) · Ruijin Hospital · NCT07085169LYL273 for Patients With Relapsed or Refractory mCRC
Phase 1/Phase 2 · 4 location(s) · Lyell Immunopharma, Inc. · NCT05319314Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Pa
Phase 2 · 1 location(s) · Sergey Orlov, MD · NCT06949982A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide i
Phase 2 · 1 location(s) · The First Hospital of Jilin University · NCT06979908A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Co
Phase 4 · 45 location(s) · Takeda · NCT06562543GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · GeneMedicine Co., Ltd. · NCT06265025177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Radiopharm Theranostics, Ltd · NCT07189871ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07012954Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/
Phase 2 · 9 location(s) · Criterium, Inc. · NCT06992258A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of C
Phase 3 · 32 location(s) · AbbVie · NCT07525206Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Phase 1 · 7 location(s) · Sairopa B.V. · NCT05856981A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Phase 1 · 6 location(s) · Sutro Biopharma, Inc. · NCT07227168A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 3 location(s) · SHY Therapeutics · NCT07705334A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorect
Phase 1/Phase 2 · 1 location(s) · BeyondBio Inc. · NCT05093907Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal
Phase 3 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06992648Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metas
Phase 1 · 8 location(s) · National Cancer Institute (NCI) · NCT06654037Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Micros
Phase 2 · 6 location(s) · Stingray Therapeutics · NCT06589440A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
Phase N/A · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06549907Sacituzumab Govitecan in Metastatic Colorectal Cancer
Phase 2/Phase 3 · 1 location(s) · University Hospital Heidelberg · NCT06243393
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.